PRESS RELEASE Neuilly-sur-Seine, France – June 19, 2025 Combined Shareholders’ Meeting of June 19, 2025:All submitted resolutions were adopted The Combined Shareholders’ Meeting of Bureau Veritas (the "Company"), chaired by Mr. Laurent Mignon, Chairman of the Board of directors, was held today at the Company’s head office. All resolutions submitted to the Shareholders’ Meeting were adopted at a large majority, including: The approval of the statutory and consolidated financial statements for the financial ...

PRESS RELEASE Paris – June 18, 2025 Bureau Veritas accelerates its LEAP | 28 strategy execution and evolves its Executive Committee Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC) is accelerating the execution of its LEAP | 28 strategy to reach its vision of being the preferred partner for its customers’ excellence and sustainability. Taking LEAP | 28 to the next level, Bureau Veritas is evolving the structure of its executive committee to drive greater organization ...

Company Overview - Fulgent Genetics, Inc. is a biotechnology company that specializes in diagnostic and genetic laboratory testing services and develops pharmaceutical treatments for various diseases and medical conditions [3] Allegations and Investigations - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Fulgent, stemming from allegations of providing potentially misleading business information to investors [1] - On February 28, 2025, Fulgent disclosed in its annual report that it received a civil investigative demand from the U.S. Department of Justice related to potential false claims submitted under the federal COVID-19 testing program for uninsured individuals [4] Market Reaction - Following the disclosure of the civil investigative demand, Fulgent's stock price declined by $0.41 per share, or approximately 2.61%, closing at $15.28 per share on March 3, 2025 [5]

PRESS RELEASE Neuilly-sur-Seine, France – May 28, 2025 Availability of preparatory documents for Bureau Veritas’ Combined Shareholders’ Meeting of June 19, 2025 Bureau Veritas’ Combined Shareholders’ Meeting will be held on Thursday, June 19, 2025, at 3:00 p.m., in the Auditorium of the Company’s registered office located at Immeuble Newtime, 40/52, boulevard du Parc in Neuilly-sur-Seine (92200), France, for the purpose of discussing the agenda and the draft resolutions contained in the preliminary Notice ...